Novartis, GBT report sickle cell data

Novartis AG (NYSE:NVS; SIX:NOVN) and Global Blood Therapeutics Inc. (NASDAQ:GBT) each reported data from studies of treatments for sickle cell disease. Novartis' data from a study of crizanlizumab (SEG101,

Read the full 299 word article

User Sign In